Erin D. Michos, MD, MHS

home / authors / erin-d-michos-md-mhs

Articles

Emerging Therapies for Hypercholesterolemia

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC

December 2nd 2022

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; provide an overview of upcoming treatment options for managing hypercholesterolemia.

The Role of Combination Therapy in Hypercholesterolemia

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 25th 2022

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.

Managing ASCVD in Patients With Statin Intolerance

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 25th 2022

A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.

Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 18th 2022

Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.

Guideline Recommendations for Lipid Lowering

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 18th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.

Less Commonly Used Lipid Lowering Agents in Hypercholesterolemia

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 11th 2022

An expert panel reviews less frequently used lipid-lowering agents in hypercholesterolemia.

Lipid Lowering Agents Beyond Statins: Bempedoic Acid

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 11th 2022

A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.

Lipid Lowering Agents Beyond Statins: Ezetimibe and PCSK9 Inhibitors

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 4th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.

Use of Statins in Management of Hypercholesterolemia

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 4th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.

Achievement of LDL-C Goals in the Real World

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 28th 2022

Alison Bailey, MD, FACC, reviews real-word data about LDL-C control and achievement of goals.

Achievement of Goals in ASCVD

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 28th 2022

A panel of experts discuss the importance of achieving low-density lipoprotein cholesterol (LDL-C) in patients.

Personalized Treatment for Patients with ASCVD

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 21st 2022

Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.

Impact of Lipid Lowering on Risk for ASCVD

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 21st 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.

Risk Enhancing Factors in ASCVD

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 14th 2022

A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

Overview of Atherosclerotic Cardiovascular Diseases (ASCVD) and Hypercholesterolemia

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 14th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.

Future Directions for the Treatment of ASCVD and Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

June 6th 2022

Drs Paul S. Jellinger, Erin D. Michos, Matthew J. Budoff, Christie Ballantyne, and Yehuda Handelsman share closing thoughts and advice for the management of ASCVD and hypercholesterolemia.

Emerging Agents for Treatment of Hypercholesterolemia and ASCVD

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

June 6th 2022

Experts in endocrinology and cardiology review novel agents in the pipeline for the management of hypercholesterolemia and ASCVD.

ASCVD and Hypercholesterolemia: Patient Selection for Bempedoic Acid

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

June 6th 2022

Erin D. Michos, MD, MHS, leads a discussion on selecting the appropriate patient populations for the use of bempedoic acid when managing atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Safety and Efficacy of Bempedoic Acid for ASCVD and Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 30th 2022

Christie Ballantyne, MD, leads a discussion on the use of bempedoic acid for the management of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia as seen in the CLEAR studies.

ASCVD and Hypercholesterolemia: Combination Therapy and Statin Intolerance

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 30th 2022

Erin D. Michos, MD, MHS; Christie Ballantyne, MD; Yehuda Handelsman, MD; and Paul S. Jellinger, MD, MACE, address the use of combination therapies and statin intolerance in patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Role of Icosapent Ethyl in Managing ASCVD and Other Lipid Disorders

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 23rd 2022

Matthew J. Budoff, MD; Paul S. Jellinger, MD, MACE; Erin D. Michos, MD, MHS; Yehuda Handelsman, MD; and Christie Ballantyne, MD, comment on the use of icosapent ethyl in reducing atherosclerotic cardiovascular disease (ASCVD) events and managing lipid disorders.

Older Agents to Manage ASCVD and Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 23rd 2022

Health care experts discuss use of older agents to control atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia in certain patient populations.

Bempedoic Acid to Manage ASCVD and Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 16th 2022

Christie Ballantyne, MD, leads a discussion on the efficacy and safety of bempedoic acid for the management of ASCVD and hypercholesterolemia.

Managing ASCVD and Hypercholesterolemia: Statins, Ezetimibe, and PCSK9 Inhibitors

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 16th 2022

Matthew J. Budoff, MD; Erin D. Michos, MD, MHS; and Paul S. Jellinger, MD, MACE, discuss the role of statins, ezetimibe, and PSCK9 inhibitors for patients with ASCVD and hypercholesterolemia.

Implementing Lifestyle Modifications for ASCVD and Hypercholesterolemia Management

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 9th 2022

Christie Ballantyne, MD, and Erin D. Michos, MD, MHS, explore the impact of lifestyle changes on managing ASCVD and hypercholesterolemia.

DCRM Practice Recommendations for ASCVD and Metabolic Diseases

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 9th 2022

Expert endocrinologists and cardiologists review the role of DCRM multispecialty practice recommendations and the use of combination therapy for patients with ASCVD and hypercholesterolemia.

Utilizing Guideline Recommendations for ASCVD and Hypercholesterolemia Management

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 2nd 2022

Drs Erin D. Michos, Matthew J. Budoff, Paul S. Jellinger, and Yehuda Handelsman, share their approach to incorporating guideline recommendations for the management of patients with ASCVD and hypercholesterolemia in clinical practice.

Management of Patients With ASCVD and Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 2nd 2022

Dr Christie Ballantyne leads a discussion on how the management of patients with ASCVD and hypercholesterolemia has changed over the years.

Impact of Comorbidities on Atherosclerosis

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

April 25th 2022

Yehuda Handelsman, MD; Christie Ballantyne, MD; Paul S. Jellinger, MD, MACE; and Erin D. Michos, MD, MHS, comment on the impact of diabetes on chronic kidney disease and cardiovascular disease.

Prevalence and Risk Factors for ASCVD Associated With Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

April 25th 2022

Matthew J. Budoff, MD; Christie Ballantyne, MD; and Paul S. Jellinger, MD, MACE, discuss the incidence and prevalence of atherosclerotic cardiovascular diseases (ASCVD) associated with hypercholesterolemia and risk factors for disease.

<1 2